For instance, identifying somatic mutations in the FLT3, NPM1, CEBPA, IDH1, IDH2, DNMT3A, TET2, and KIT genes provided important information that improved AML diagnosis, treatment stratification, and monitoring [10,11,12]. This evidence concerns the gene IDH1 and acute myeloid leukemia.